Clinical Trials Browser

Phase 2/3 × Neuromyelitis Optica × eculizumab × Clear all

NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Phase 2/3 Terminated

5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence